Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

Phase 2UnknownNCT01120002

Osaka City University50 enrolled

Overview

A double blind, placebo-controlled randomized study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Alzheimer's Disease

Tamibarotene is a synthetic retinoid presently approved in Japan for the treatment of APL, which has a higher receptor selectivity and activity for the Retinoic Acid Receptor subtypes compared to the natural retinoid. Tamibarotene decreased insoluble amyloid-beta (Ab) 42 deposition in APP mice, and also increased TTR, VAChT and ACh in the brain of SAMP8 mice, which suggest the enhancement of neurotransmission. In the behavioral model such as reduced anxiety of SAMP8 mice and rat passive avoidance test, tamibarotene showed improvement. Tamibarotene as in other retinoids are known to moderate the immune system and reduce inflammatory cytokines and chemokines, which may control the excessive stimulation of astrocyte and microglia around the Ab plaque. Tamibarotene reduced cytokines and showed clinical efficacy in the rat experimental autoimmune encephalitis model. Furthermore, retinoids are known to have critical roles during the regeneration stage in the differentiation from neural stem cells (NSC). In spinal cord injured rats treated with tamibarotene showed better recovery compared to the control. By these preclinical results, we plan by this study to evaluate the efficacy together with the safety of tamibarotene to the patients of Alzheimer's Disease. Tamibarotene is used clinically in Japan since 2005. It's side effects are known to be similar to that of other clinically used retinoids.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Alzheimer's Disease

Interventions

TamibaroteneDRUG

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

PlaceboDRUG

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Japanese patients who are diagnosed as probable Alzheimer' Disease according to NINCDS-ADRDA criteria * Diagnosed by brain diagnostic imaging (CT, MRI) within six months before the consent and no occurrence of the event after that to suggest cerebral vascular disease * Mild to Moderate Alzheimer's Disease of MMSE from 10 to 26 * Age from 55 to 80 * Treated for a minimum of 12 weeks with a stable dose of donepezil and willing to continue the same during the trial period * For women Menopause ≥ 2 years * For men contraceptive measures are required during the study and after 6 months * In principle patients should be living at their home in the presence of a caregiver who is defined as a healthy person in contact with the patient for more than 10 hours a week, could provide required information of the behavior and activities of daily living, accompany all the clinical examination, and supervise the handling and administration of the drug throughout the study period. * Patients who could take pills as a whole * Patient, caregiver and patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form Exclusion Criteria: * Any cause of dementia not due to Alzheimer's disease * Past history of other central nervous condition or psychiatric disease * Symptom of depression and drug addiction * Impairment in the physical function by other factor than the Alzheimer's Disease * Patients who are expected to move in to care facilities during the study period * triglyceride \> 400 mg/dL

Locations (1)

Osaka City University Hospital

Osaka, Japan

RECRUITING

Outcomes

Primary Outcomes

Changes in Alzheimer's Disease Assessment Scale (ADAS-JCog)

Time frame: baseline, 12 weeks, 24 weeks

Secondary Outcomes

Changes in Mini-Mental State Examination (MMSE)

Time frame: baseline, 12 weeks, 24 weeks

Changes in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

Time frame: baseline, 12 weeks, 24 weeks

Changes in Clinician Interview-Based Assessment of Change Plus Caregiver Information (CIBIC-Plus)

Time frame: baseline, 12 weeks, 24 weeks

Central Contacts

Takami Miki, MD

CONTACT

+81-6-6645-212 ""miki."@med.osaka-cu.ac.jp"

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.